Ovarian Cancer | Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Robert L Coleman, Stephanie Lheureux, Joyce F Liu and Kathleen Moore. Considerations for the use of a PARP inhibitor as a component of up-front treatment for patients with ovarian cancer (OC) (00:00) Selection of mutation assay for patients with newly diagnosed OC (5:27) PARP inhibitor maintenance therapy for newly diagnosed OC; recently FDA-approved options (13:55) Integration of PARP inhibitor monotherapy or combination with bevacizumab into maintenance therapy for newly diagnosed OC (24:47) Can homologous recombination deficiency testing guide therapeutic decision-making for patients with OC? (34:20) Treatment approach for patients who experience disease progression on a PARP inhibitor; potential role of switching to another PARP inhibitor (40:04) Clinical care of patients who receive a PARP inhibitor and experience side effects or other tolerability issues requiring dose adjustment or discontinuation (44:24) “Manage Wisely: PARP inhibitor treatment and adverse events” (53:17) Design, efficacy and safety findings from the Phase III VELIA trial evaluating veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC; implications for clinical practice (58:47) Choice of PARP inhibitor for patients with platinum-sensitive OC (1:08:08) ASCO 2020 Abstract 6002: Final overall survival results from SOLO2/ENGOT-ov21: A Phase III trial assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (1:15:06) CME information and select publications